Wealthy nations that account for just 14 per cent of the global population have pre-ordered just over half of the vaccine doses expected to be produced by the 13 leading developers next year, researchers from the Johns Hopkins Bloomberg School of Public Health found, The New Indian Express (TNIE) reported quoting AFP.
Even if the drug makers all produce effective, safe vaccines and meet their maximum global manufacturing targets, the study said “at least a fifth of the world’s population would not have access to vaccines until 2022”.
The research looked at publicly available data and found that as of mid-November, reservations totalled 7.48 billion doses, equivalent to 3.76 billion immunisation courses, because most vaccines require two jabs. That is out of a total maximum projected manufacturing capacity of 5.96 billion courses by the end of 2021.
The study estimated that up to 40 percent of the vaccine courses from the leading manufacturers might be available for low-and middle-income countries, but said this would depend on how rich countries share what they have bought, the report added.
The authors, who cautioned that public information was incomplete, called for “greater transparency and accountability” over support for equitable global access. They suggested the implications could go well beyond health.
“To varying degrees, trade with and travel to countries might face continued disruption until access to effective preventive or treatment measures, such as COVID-19 vaccines, becomes more widely available,” the report said.
Many countries have joined a pooled purchasing mechanism COVAX, coordinated by the World Health Organisation, the Coalition for Epidemic Preparedness Innovations and vaccines alliance Gavi — aiming to ensure that people across the world have access to a Covid-19 vaccine, regardless of wealth.
The initiative is hoping to have two billion doses available by the end of 2021. But neither the United States nor Russia has so far joined the programme.